95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
BRIEF RESEARCH REPORT article
Front. Med.
Sec. Family Medicine and Primary Care
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1543158
This article is part of the Research Topic Exploring Chronic Fatigue: Neural Correlates, Mechanisms, and Therapeutic Strategies View all 8 articles
Medication Use and Symptomology in North American Women with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Provisionally accepted
Angela Pochakom 1*
Gillian Macnevin 1
Robyn F Madden 2
Amy C Moss 2 Julia M Martin 1 Sophie Lalonde- Bester 3
Jill Parnell 2 Eleanor Stein 1
Jane Shearer 1*- 1 University of Calgary, Calgary, Canada
- 2 Mount Royal University, Calgary, Alberta, Canada
- 3 University of Alberta, Edmonton, Alberta, Canada
Background: There are no known curative treatments for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and current therapeutic regimens often yield inconsistent results.Despite the profound physical and mental burden experienced by those living with ME/CFS, patients often face a trial-and-error process in finding medications that offer some relief. This study surveyed 135 North American women diagnosed with ME/CFS to characterize medication use in relation to disease features, symptomology, and function.Medications were classified into 9 categories according to their primary mechanism of action and therapeutic use.Participants were primarily middle-aged (47.1± 5.3 years) and were diagnosed for a mean duration of 8.4±9.5 years (mean±SD). Responses showed 68.6% of participants reported taking medications specifically for ME/CFS. Of those taking ME/CFS-related symptom medications, the average use was 3.0 medications per patient, with higher use in US compared to Canadian participants. Analgesic medications (31.7%) were the most frequently used, followed by psychotropic (26.4%), and immune-related medications (10.6%).These trends persisted across different symptom profiles, apart from gastrointestinal associated medication use replacing immune related medications in those with gastrointestinal, neurological, and psychiatric symptoms. There was no significant correlation found between the number of medications used with disease duration, age, or age at diagnosis. However, a U-shaped relationship between ME/CFS-related symptom medication use and functional capacity as assessed by self-reported physical movement (hours/week) was evident. Conclusions: Our study highlights the diverse and complex patterns in pharmacological treatment regimens for ME/CFS in women, while also underscoring the need for more tailored and evidence-based therapeutic strategies to address the varied symptom profiles.
Keywords: ME/CFS, clinical, drugs, functional capacity, female
Received: 10 Dec 2024; Accepted: 03 Apr 2025.
Copyright: © 2025 Pochakom, Macnevin, Madden, Moss, Martin, Lalonde- Bester, Parnell, Stein and Shearer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Angela Pochakom, University of Calgary, Calgary, Canada
Jane Shearer, University of Calgary, Calgary, Canada
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.